


XV
Reunión anual
PAMPLONA
20/21/22 junio

Impacto del cribado de cáncer de mama

Nieves Ascunce



**Red de Programas
de Cribado de Cáncer**



100% de cobertura
Más de 5.000.000 mujeres

Annals of Oncology 21 (Supplement 3): iii43–iii51, 2010
doi:10.1093/annonc/mdq085

Cancer screening in Spain

N. Ascunce^{1*}, D. Salas², R. Zubizarreta³, R. Almazán³, J. Ibáñez², M. Ederra¹ & representatives
of the Network of Spanish Cancer Screening Programmes (*Red de Programas Españoles de
Cribado de Cáncer*)

Table 2. Characteristics of Spanish breast cancer screening programmes

Autonomous region	Year programme started	Year 100% coverage	Age group	Women invited 2007 (n)
Andalusia	1995	2005	45–69	319 721 ^a
Aragon	1997	2006	50–69	52 425
Principality of Asturias	1991	2000	50–69	54 561
Balearic Isles	1997	2009	50–69	33 992
Canary Islands	1999	2005	50–69	NA
Cantabria	1997	1997	50–69	32 540
Castile-La Mancha	1992	1997	45–69	121 036
Castile-León	1992	1996	50–69	NA
Catalonia	1992	2004	50–69	341 045
Valencian region	1992	2001	45–69	243 546
Extremadura	1998	2005	50–69	55 900
Galicia	1992	1998	50–69	136 564
Madrid (region)	1999	2001	50–69	301 227
Murcia (region)	1995	1999	50–69	60 798
Navarre	1990	1992	45–69	44 084
Basque Country	1995	2000	50–69	116 228
La Rioja	1993	1995	45–69	16 759
Autonomous City of Ceuta	2001	2006	45–69	651
Autonomous City of Melilla	1997	1997	45–69	NA
Total				

^aData corresponding to 80% of the autonomous region.

Indicadores predictores


- Participación
- Tasa de detección
- Características de los tumores detectados



Resultados de Prog.




Resultados de Prog.




Impacto del cribado de cáncer de mama

Indicadores predictores Cánceres de Intervalo



Impacto del cribado de cáncer de mama



¿ Mortalidad ?

Impacto del cribado de cáncer de mama




Figure 1. Mortality trends among men and women for selected types of cancer: Spain, 1980–2007.

Punto de cambio

**% anual de cambio
Hasta 1992 Desde 1992**

2,9 (2,5 ; 3,4) -2,0 (-2,3 ; -1,8)


Cancer mortality trends in Spain: 1980–2007

A. Cabanes^{1,2*}, E. Vidal^{1,2}, N. Aragón^{1,2}, B. Pérez-Gómez^{1,2}, M. Pollán^{1,2}, V. Lope^{1,2} & G. López-Abente^{1,2}

¹Cancer and Environmental Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid and ²Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública – CIBERESP), Spain

Annals of Oncology 21 (Supplement 3): iii14–iii20, 2010

Impacto del cribado de cáncer de mama



Age-specific breast, uterine and ovarian cancer mortality trends in Spain:
Changes from 1980 to 2006

Anna Cabanes ^{a,b,*}, Enrique Vidal ^{a,b}, Beatriz Pérez-Gómez ^{a,b}, Nuria Aragonés ^{a,b},
Gonzalo López-Abente ^{a,b}, Marina Pollán ^{a,b}

^aÁrea de Epidemiología Ambiental y Cáncer, Centro Nacional de Epidemiología (CNE), Instituto de Salud Carlos III (ISCIII), Monforte de Lemos 5, 28029 Madrid, Spain
^bCIBER in Epidemiology and Public Health (CIBERESP), Spain

Impacto del cribado de cáncer de mama

Tabla 4.27. Tendencias de mortalidad por cáncer de mama por comunidad autónoma, 1975-2006.

CCAA	Nº puntos cambio	Global PCA	Periodo 1	PCA 1	Periodo 2	PCA 2	Periodo 3	PCA 3	Periodo 4	PCA 4
Andalucía	1	0.60	1975-1993	2.10	1993-2006	-1.40	-	-	-	-
Aragón	2	0.00	1975-1981	-1.50	1981-1987	6.90	1987-2006	-1.80	-	-
Asturias	1	0.10	1975-1991	1.70	1991-2006	-1.50	-	-	-	-
Islas Baleares	1	0.30	1975-1993	2.60	1993-2006	-4.10	-	-	-	-
Islas Canarias	1	-0.50	1975-1992	2.40	1992-2006	-3.60	-	-	-	-
Cantabria	1	0.00	1975-1994	1.50	1994-2006	-2.70	-	-	-	-
Castilla La Mancha	1	0.40	1975-1994	1.70	1994-2006	-1.90	-	-	-	-
Castilla León	1	0.40	1975-1992	2.90	1992-2006	-2.40	-	-	-	-
Cataluña	1	-0.30	1975-1992	2.00	1992-2006	-3.00	-	-	-	-
Comunidad Valenciana	1	0.10	1975-1993	1.80	1993-2006	-2.40	-	-	-	-
Extremadura	1	0.40	1975-1991	2.60	1991-2006	-1.90	-	-	-	-
Galicia	1	0.40	1975-1991	2.70	1991-2006	-1.90	-	-	-	-
Madrid	3	0.60	1975-1984	0.40	1984-1987	11.90	1987-1995	0.70	1995-2006	-2.80
Murcia	1	0.50	1974-1994	2.20	1994-2006	-2.20	-	-	-	-
Navarra	1	-0.80	1975-1994	1.10	1994-2006	-4.20	-	-	-	-
País Vasco	1	-0.20	1975-1991	2.50	1991-2006	-2.90	-	-	-	-
La Rioja	1	-0.10	1975-1993	3.30	1993-2006	-5.00	-	-	-	-
España	3	0.20	1976-1986	2.00	1986-1988	4.30	1988-1993	0.80	1993-2006	-2.30

A. Cabanes, B. Pérez-Gómez, N. Aragónés, M. Pollán, G. López-Abente. La situación del cáncer en España, 1975-2006. Instituto de Salud Carlos III. Madrid, 2009

Age-Specific Spatio-Temporal Patterns of Female Breast Cancer Mortality in Spain (1975–2005)

MARÍA D. UGARTE, PhD, TOMÁS GOICOA, PhD, JAIONE ETXEBERRIA, MSC,
ANA F. MILITINO, PhD, AND MARINA POLLÁN, MD, PhD

Ann Epidemiol 2010;20:906–916.




FIGURE 5. Breast cancer mortality risks spatio-temporal distribution between 1975–2005 for women aged between 45–64 years. Note that Canary Island have changed their exact location. They are shown inside the rectangle at the bottom right corner.

CONCLUSIONS: A different behavior for breast cancer mortality risks is observed for different provinces among the age specific groups. The decline of mortality is delayed for the oldest age group. Province differences in the implementation of screening programs could explain some of the observed differences.

The results show that there was a reduction in breast cancer mortality throughout the period studied, and that this reduction was more marked after the breast cancer-screening program was introduced. In the post-intervention period, there is a statistically significant annual decline of 5%, whereas before intervention it was 1%. However, we have not observed a steeper decline in those areas where the Program was implemented earlier, compared to the control area. On the other hand, by the time the Program had been implemented in all four-city zones (years 2003–2004), mortality had fallen by 17% with respect to when there was no screening program. Even so, we cannot affirm that this reduction be due to the Program alone.

Breast cancer mortality in Barcelona following implementation of a city breast cancer-screening program

Mariola Pons-Vigués MPH^{a,b,*}, Rosa Puigpinós MPH^{a,b}, Gemma Cano-Serral MPH^b, Marc Marí-Dell'Olmo MPH^{a,b}, Carme Borrell PhD^{a,b,c}

^aCIBER de Epidemiología y Salud Pública (CIBERESP), Spain

^bAgència de Salut Pública de Barcelona, Plaça Lassa 1, 08023 Barcelona, Spain

^cUniversitat Pompeu Fabra, Barcelona, Spain

Table 2

Breast cancer mortality trends before and after introduction of the populational breast cancer screening program. Annual relative risk (RR) with 95% confidence interval (95%CI) for Barcelona as a whole, and for each zone

	Before introduction		After introduction	
	Annual RR	95%CI	Annual RR	95%CI
Zone 1	1.00	0.98–1.03	0.95	0.91–1.01
Zone 2	1.00	0.98–1.01	1.02	0.92–1.12
Zone 3	1.00	0.99–1.01	0.90	0.78–1.04
Zone 4	0.97*	0.96–1.98	0.91	0.51–1.62
Barcelona	0.99*	0.98–0.99	0.95*	0.92–1.99

Models adjusted for age and ICEF.

* p-value < 0.05




Figure 2 Breast cancer aged-adjusted (European standard) mortality by three-year periods and age groups, 1975–2004

Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme

Elizaga N Ascunce, C Moreno-Iribas, A Barcos Urtiaga, E Ardanaz, M Ederra Sanz, J Castilla and N Egüés

J Med Screen 2007;14:14-20

Table 4 Estimation of the breast cancer screening programme effect on mortality by age group

	All ages	30-44 years	50-69 years	≥75 years
<i>All breast cancer deaths</i>				
<i>Pre-screening period (1986-90)</i>				
Breast cancer deaths (n)	374	32	185	94
Mortality rate/100,000	25.1	12.8	64.0	100.6
<i>Last screening period (1997-2001)</i>				
Breast cancer deaths (n)	389	37	123	154
Mortality rate/100,000	20.1	12.4	41.5	106.6
Relative risk (95% CI)	0.80 (0.69-0.93)	0.97 (0.60-1.56)	0.65 (0.51-0.82)	1.06 (0.82-1.37)
<i>Breast cancer deaths excluding prevalent cases</i>				
<i>Pre-screening period (1986-90)</i>				
Breast cancer deaths (n)	308	29	150	77
Mortality rate/100,000	20.8	11.5	51.9	81.8
<i>Last screening period (1997-2001)</i>				
Breast cancer deaths (n)	301	37	88	121
Mortality rate/100,000	15.6	12.4	30.0	84.3
Relative risk (95% CI)	0.75 (0.63-0.89)	1.07 (0.66-1.74)	0.58 (0.44-0.75)	1.03 (0.77-1.37)


Age adjusted to European standard population

RESEARCH ARTICLE

Open Access

Breast cancer incidence and overdiagnosis in Catalonia (Spain)

Montserrat Martinez-Alonso^{1,2†}, Ester Vilaprinyo^{3†}, Rafael Marcos-Gragera^{4,5}, Montserrat Rue^{1,2*}




- Background incidence %MX=0
- Expected Incidence %MX
- Observed Incidence

Table 2 Overdiagnosis estimation by year of birth in Catalonia

Cohort	Overdiagnosis (%)	[95% conf. interval]
1935	0.4	-8.8 12.2
1940	23.3	9.1 43.4
1945	30.6	12.7 57.6
1950	46.6	22.7 85.2

Impacto del cribado al cáncer de mama

Cumulative False Positive Risk Research Group (alphabetical order): Almazán R; Ascunce N; Baré M; Baroja A; Belvis F; Castells X; Cuevas D; De la Vega M; Delfrade J; Díez de la Lastra I; Ederra M; Fernández AB; Galceran J; González-Román I; Ibáñez J; Macià F; Natal C; Queiro MT; Román R; Sala M; Salas D; Velarde JM; Vidan J; Zubizarreta R.



Annals of Oncology Advance Access published March 23, 2011

Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening

R. Román^{1,2}, M. Sala^{1,2}, D. Salas³, N. Asunción^{2,4}, R. Zubizarreta⁵, X. Castells^{1,2,6*} & Cumulative False Positive Risk Group



Riesgo Acumulado de Falso Positivo




Figure 1. Cumulative risk and hazard risk of a false-positive result for any procedure for women starting screening at age 50–51 years. Highest risk reading, one view, film-screen mammography, premenopausal status, previous invasive procedures, and familial breast cancer) versus lowest risk (opposite categories).




Figure 2. Cumulative risk and hazard risk of a false-positive result for invasive procedures for women starting screening at age 50–51 years. Highest risk (double reading, two views, not using HRT, premenopausal status, previous invasive procedures, and familial breast cancer) versus lowest risk profiles (opposite categories). HRT, hormone replacement therapy.

Eur Radiol (2011) 21:2083–2090
DOI 10.1007/s00330-011-2160-0

BREAST

Effect of radiologist experience on the risk of false-positive results in breast cancer screening programs

Raquel Zubizarreta Alberdi · Ana B. Fernández Llana · Raquel Almazán Ortega · Rubén Roman Expósito · José M. Velarde Collado · Teresa Quieiro Verdes · Carmen Natal Ramos · María Ederra Sanz · Dolores Salas Trejo · Xavier Castells Olivares · and the CFPR (Cumulative False Positive Risk) group(1)

Eur Radiol (2011) 21:2083–2090
DOI 10.1007/s00330-011-2160-0

Preventive Medicine 53 (2011) 76–81
Contents lists available at ScienceDirect
Preventive Medicine
journal homepage: www.elsevier.com/locate/ypmed

ELSEVIER

Effect of start age of breast cancer screening mammography on the risk of false-positive results
Dolores Salas ^{a,*}, Josefina Ibáñez ^{a,1}, Rubén Román ^{b,2}, Dolores Cuevas ^{c,3}, María Sala ^{b,2}, Nieves Asunción ^{d,4}, Raquel Zubizarreta ^{e,5}, Xavier Castells ^{b,2} and the CFPR (Cumulative False Positive Risk) group ⁶

Eur Radiol (2012) 22:331–340
DOI 10.1007/s00330-011-2263-7

BREAST

Impact of intermediate mammography assessment on the likelihood of false-positive results in breast cancer screening programmes

Nieves Asunción · María Ederra · Josu Delfrade · Araceli Barroja · Nieves Erdózain · Raquel Zubizarreta · Dolores Salas · Xavier Castells · the Cumulative False Positive Risk (CFPR) Group



**La controversia sullo screening mammografico:
Un primo bilancio dei benefici e dei danni dello screening
per il tumore della mammella in Europa.**

Aspetti metodologici e risultati

**Eugenio Paci
Instituti per lo studio e
la prevenzione oncologica**